RxDoctor Payments Data

Shyam Moudgil, MD

Neurology · Roseville, MINPI 1740390848

Payments from drug & device makers

$16,302in general payments, 2019–2025

Across 843 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Biogen$2K
  • Novartis$2K
  • EMD Serono, Inc.$1K
  • Neurocrine Biosciences, Inc.$799
  • Neurelis, Inc.$783
  • plus $8K from 50 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$16,270100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.119$2,083
Biogen85$1,868
Novartis132$1,769
EMD Serono, Inc.65$1,223
Neurocrine Biosciences, Inc.25$799
Neurelis, Inc.33$783
Teva Pharmaceuticals USA, Inc.33$616
Pfizer31$483
Bristol Myers Squibb27$468
Eisai Inc.20$450
Lilly USA, LLC24$410
SK Life Science, Inc.12$375
Amgen(2 entities)17$312
Jazz Pharmaceuticals Inc.15$305
AbbVie(2 entities)17$279
Argenx US, Inc.11$269
Vanda Pharmaceuticals Inc.10$243
Otsuka America Pharmaceutical, Inc.12$242
AstraZeneca10$237
Avanir Pharmaceuticals, Inc.11$221
Genentech USA, Inc.8$220
Sanofi10$214
Amneal Pharmaceuticals LLC10$207
Aquestive Therapeutics, Inc.10$186
Adamas Pharmaceuticals, Inc.10$172
Acadia Pharmaceuticals Inc6$172
Aucta Pharmaceuticals, Inc.10$170
Catalyst Pharmaceuticals, Inc.7$167
TG Therapeutics, Inc.4$162
Upsher-smith Laboratories LLC9$154
Greenwich Biosciences, Inc.4$100
Sunovion Pharmaceuticals Inc.5$78
Avadel CNS Pharmaceuticals, LLC3$68
Otter Pharmaceuticals, LLC2$58
Corium, LLC3$58
Johnson & Johnson3$57
E.r. Squibb & Sons, L.L.C.4$56
Takeda Pharmaceuticals U.S.A., Inc.2$53
Supernus Pharmaceuticals, Inc.2$47
Xeris Pharmaceuticals, Inc.2$41
Assertio Therapeutics, Inc.2$39
Kyowa Kirin, Inc.2$37
Harmony Biosciences LLC1$37
Axsome Therapeutics, Inc.1$34
Nevro Corp.1$33
Sanofi-aventis U.S. LLC2$33
Biohaven Pharmaceutical Holding Company Ltd.2$27
Nobelpharma America, LLC1$27
Cycle Pharmaceuticals Inc1$26
Alnylam Pharmaceuticals Inc.1$24
Aprecia Pharmaceuticals, LLC1$23
Boston Scientific1$22
Banner Life Sciences, LLC1$19
Acorda Therapeutics, Inc1$16
Livanova USA, Inc.1$14
Mallinckrodt Hospital Products Inc.1$13

How this compares

$16,302 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$148,845
Medicare patients
528
Services billed
1,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab28$270,394
AustedoDeutetrabenazine20$183,901
Avonex Pen (4 Pack)Interferon Beta-1a16$134,193
SympazanClobazam27$69,780
FingolimodFingolimod Hcl13$61,582
GlatopaGlatiramer Acetate13$59,710
BriviactBrivaracetam40$54,388
NuedextaDextromethorphan Hbr/Quinidine28$52,140
Glatiramer Acetate12$34,286
Aimovig AutoinjectorErenumab-Aooe35$27,189
Lacosamide228$18,252
Pyridostigmine Bromide ErPyridostigmine Bromide11$17,413
Emgality PenGalcanezumab-Gnlm15$10,123
Levetiracetam388$9,632
Rufinamide11$7,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$616$183,90120 claims
Aquestive Therapeutics, Inc.Sympazan$186$69,78027 claims
UCB, Inc.Briviact$2,083$54,38840 claims
Avanir Pharmaceuticals, Inc.Nuedexta$221$52,14028 claims
Upsher-smith Laboratories LLCTopiramate$154$996141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →